GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (NAS:PRPO) » Definitions » Earnings Yield (Joel Greenblatt) %

Precipio (Precipio) Earnings Yield (Joel Greenblatt) % : -65.79% (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Precipio Earnings Yield (Joel Greenblatt) %?

Precipio's Enterprise Value for the quarter that ended in Dec. 2023 was $8.84 Mil. Precipio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.84 Mil. Precipio's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -65.79%.

The historical rank and industry rank for Precipio's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

PRPO' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -244.68   Med: -50.39   Max: -14.18
Current: -73.53

During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Precipio was -14.18%. The lowest was -244.68%. And the median was -50.39%.

PRPO's Earnings Yield (Joel Greenblatt) % is ranked worse than
88.31% of 231 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.28 vs PRPO: -73.53

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Precipio's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Precipio Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Precipio's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precipio Earnings Yield (Joel Greenblatt) % Chart

Precipio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -56.18 -28.74 -33.11 -114.94 -65.79

Precipio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -114.94 -72.46 -116.28 -120.48 -65.79

Competitive Comparison of Precipio's Earnings Yield (Joel Greenblatt) %

For the Diagnostics & Research subindustry, Precipio's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precipio's Earnings Yield (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Precipio's Earnings Yield (Joel Greenblatt) % falls into.



Precipio Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Precipios Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-5.835/8.84478
=-65.97 %

Precipio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.84 Mil.



Precipio  (NAS:PRPO) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Precipio Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Precipio's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Precipio (Precipio) Business Description

Traded in Other Exchanges
N/A
Address
4 Science Park, New Haven, CT, USA, 06511
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings.
Executives
Richard A Sandberg director 330 NEVEDA STREET, NEWTON MA 02460-1458
Ahmed Zaki Sabet officer: Chief Operations Officer 33 ANDYS DR, EAST HAVEN CT 06512
Ilan Danieli director, officer: Chief Executive Officer 14707 CALIFORNIA STREET, SUITE 5, OMAHA NE 68154
Matthew Gage officer: Chief Financial Officer 56 STAGECOACH CIRCLE, MILFORD CT 06460
David Seth Cohen director, 10 percent owner C/O STANDARD OIL, 299 BISHOP AVENUE, BRIDGEPORT CT 06610
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Kathleen Laporte director
Robert Patzig director THE GOVERNOR TYLER, 1881 GROVE AVENUE, RADFORD VA 24141
Michael A Luther director 21 CORPORATE CIRCLE, ALBANY NY 12203
Jeffrey Cossman director C/O PRECIPIO INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Carl Iberger officer: Chief Financial Officer C/O PRECIPIO, INC., 12325 EMMET STREET, OMAHA NE 68164
Douglas Fisher director 587 PATROL RD, WOODSIDE CA 94062
Mark Rimer director, 10 percent owner C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511

Precipio (Precipio) Headlines

From GuruFocus

Precipio Signs Another Major HemeScreen� Customer

By Stock market mentor Stock market mentor 01-11-2023

Precipio Signs Additional Major HemeScreen� Customer

By Value_Insider Value_Insider 12-06-2022

Precipio Signs Another HemeScreen� Customer

By sperokesalga sperokesalga 05-04-2023

Precipio Granted 180-day Extension From NASDAQ To Regain Compliance

By sperokesalga sperokesalga 04-27-2023

Precipio Shares Growth Catalysts For HemeScreen

By sperokesalga sperokesalga 05-17-2023

Precipio Announces Q3-2023 Shareholder Update Call

By GlobeNewswire 11-16-2023